1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSmall Business Innovation Research (SBIR) Program – Medical Devices is sponsored by National Institutes of Health (NIH). Encourages small businesses to engage in research and development with the potential for product commercialization in medical devices.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) | National Institute of General Medical Sciences NIH has congressionally mandated set-aside programs for U.S. small businesses to engage in research and development activities that have strong potential for commercialization. Awards are intended to: Stimulate technological innovation. Use small business to meet federal research and development needs.
Increase private sector commercialization of innovations derived from federal research and development. The NIH SBIR/STTR program consists of two phases: Phase 1 (R41/R43) establishes the scientific and technical merit and feasibility as well as the potential for commercialization of the proposed Phase 2 (R42/R44) continues research or research and development (R&D) efforts initiated in Phase 1.
NIH SBIR/STTR grant solicitation announcements and additional information are website. You can also find information on the difference between SBIR and STTR application requirements . NIGMS-Specific SBIR Guidance The goal of NIGMS is to support innovative SBIR projects that could benefit the research communities related to its mission.
SBIR/STTR grant applications are accepted in most of the scientific areas for which the Institute provides support. Specific topics of research interest to NIGMS [PDF] . The NIGMS SBIR program like the vast majority of NIGMS-funded research is investigator-initiated.
Applicants propose what to do, how to do it, and the best path toward commercialization. NIGMS will not accept applications with budget requests exceeding the statutory budget limitations defined in the specific SBIR/STTR notice of considered to fit one or more of the SBA-approved topics for awards over the statutory budget limitations listed in SBA-Approved Waiver Topics of the SBIR/STTR Program Descriptions and Topics .
Applicants who are considering a project with a budget exceeding the hard budget cap defined in the notice of funding opportunity should contact the NIGMS SBIR coordinator early in the process of application preparation and at least six weeks prior to the anticipated submission due date. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
NIGMS support of Phase 2B competing renewal grant applications is limited and should be discussed in advance with the NIGMS SBIR coordinator. NIGMS does participate in the Commercialization Readiness Pilot (CRP) program designed to facilitate the transition of previously funded SBIR and STTR Phase 2 and Phase 2B projects to the commercialization stage by providing additional support for technical assistance.
List of NIGMS funding announcements (program announcements, requests for applications and notices) for the SBIR For information about NIGMS SBIR/STTR grants administration and management, NIGMS_GAB_SBIR@nigms. nih. gov .
NIH Research Evaluation and Commercialization Hub (REACH) The NIH Research Evaluation and Commercialization Hub (REACH) program was established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs.
Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH’s mission. For more information REACH and current For information about NIGMS SBIR programs, email Eddie Billingslea, Ph. D.
This page last updated on
According to the current listing, eligibility includes: Small businesses with fewer than 500 employees, at least 50% U. S. -owned. Confirm the full requirements in the official notice before applying.
The current listing shows up to $275,000 for Phase I; up to $1,250,000 for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Business Innovation Research (SBIR) Program – Medical Devices is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article